公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2021 | Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance | Wang, Yulei; LI-CHUN LU ; Guan, Yinghui; MING-CHIH HO ; Lu, Shan; Spahn, Jessica; CHIH-HUNG HSU | Experimental hematology & oncology | 15 | 15 | |
2014 | Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy | LI-CHUN LU ; YU-YUN SHAO ; Chan S.-Y.; CHIH-HUNG HSU ; ANN-LII CHENG | Anticancer Research | 12 | 10 | |
2019 | Considerations of heterogeneity in clinical trials for hepatocellular carcinoma | TSUNG-HAO LIU ; YU-YUN SHAO ; LI-CHUN LU ; Ying-Chun Shen ; CHIUN HSU ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; ANN-LII CHENG | Expert Review of Gastroenterology and Hepatology | 5 | 7 | |
2019 | Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma | LI-CHUN LU ; CHIUN HSU ; YU-YUN SHAO ; Chao Y.; Yen C.-J.; I-LUN SHIH ; Hung Y.-P.; Chang C.-J.; Ying-Chun Shen ; JHE-CYUAN GUO ; TSUNG-HAO LIU ; CHIH-HUNG HSU ; ANN-LII CHENG | Liver Cancer | 46 | 44 | |
2019 | Early alpha‐foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma | YU-YUN SHAO ; TSUNG-HAO LIU ; CHIUN HSU ; LI-CHUN LU ; YING-CHUN SHEN ; ZHONG-ZHE LIN ; ANN-LII CHENG ; CHIH-HUNG HSU | Liver International | 56 | 58 | |
2013 | Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma | LI-CHUN LU ; YU-YUN SHAO ; Kuo R.N.C.; ZHONG-ZHE LIN ; Yeh Y.-C.; Shau W.-Y.; CHIH-HUNG HSU ; ANN-LII CHENG ; Lai M.-S. | Cancer | 11 | 11 | |
2022 | ICOS-Positive Regulatory T Cells in Hepatocellular Carcinoma: The Perspective from Digital Pathology Analysis | LI-CHUN LU ; Deantonio, Cecilia; Palu, Cintia C; Lee, Yi-Hsuan; Mitchell, Laura S; Cowan, Marianne; Corser, Matthew; Sherry, Lorcan; ANN-LII CHENG ; Quaratino, Sonia; YU-YUN SHAO ; Sainson, Richard C A; CHIH-HUNG HSU | Oncology (Switzerland) | 0 | 0 | |
2019 | Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment | LI-CHUN LU ; Lee, Yi Hsuan; Chang, Chun Jung; CHIA-TUNG SHUN ; Fang, Chih Yeu; YU-YUN SHAO ; TSUNG-HAO LIU ; ANN-LII CHENG ; CHIH-HUNG HSU | Liver Cancer | 45 | 41 | |
2011 | Increasing incidence of brain metastasis in patients with advanced Hepatocellular carcinoma in the era of Antiangiogenic targeted therapy | YU-YUN SHAO ; LI-CHUN LU ; ANN-LII CHENG ; CHIH-HUNG HSU | Oncologist | 34 | 28 | |
2016 | Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma | Lin H.-H.; Feng W.-C.; LI-CHUN LU ; YU-YUN SHAO ; CHIH-HUNG HSU ; ANN-LII CHENG | Cancer letters | 36 | 39 | |
2021 | Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy | YING-CHUN SHEN ; Yeh C.-P.; YUNG-MING JENG ; CHIUN HSU ; CHIH-HUNG HSU ; ZHONG-ZHE LIN ; YU-YUN SHAO ; LI-CHUN LU ; TSUNG-HAO LIU ; CHIEN-HUNG CHEN ; ANN-LII CHENG | Cancers | 2 | 2 | |
2012 | Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer | LI-CHUN LU ; YU-YUN SHAO ; CHIH-HUNG HSU ; CHIUN HSU ; WEN-FANG CHENG ; YU-LIN LIN ; ANN-LII CHENG ; KUN-HUEI YEH | Anticancer Research | 0 | | |
2021 | Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma | SHIH-HUNG YANG ; LI-CHUN LU ; HSIANG-FONG KAO ; BANG-BIN CHEN ; TING-CHUN KUO ; SUNG-HSIN KUO ; YU-WEN TIEN ; Bai, Li-Yuan; ANN-LII CHENG ; KUN-HUEI YEH | Oncoimmunology | 3 | 4 | |
2022 | Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience | Wang, Yu-Wen; Tsai, Cheng-Hong ; HSIN-AN HOU ; FENG-MING TIEN ; JIA-HAU LIU ; WEN-CHIEN CHOU ; BOR-SHENG KO ; Chen, Yu-Wen; CHIEN-CHIN LIN ; Chieh-Lung Cheng ; Lo, Min-Yen; YUN-CHU LIN ; LI-CHUN LU ; SHANG-JU WU ; SUNG-HSIN KUO ; RUEY-LONG HONG ; TAI-CHUNG HUANG ; MING YAO | Annals of hematology | 10 | 9 | |
2017 | Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population study | LI-CHUN LU ; PEI-JER CHEN ; Yeh Y.-C.; CHIH-HUNG HSU ; Chen H.-M.; Lai M.-S.; YU-YUN SHAO ; ANN-LII CHENG | Anticancer Research | 15 | 16 | |
2022 | Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment | Chen, Ching-Tso; Feng, Yin-Hsun; Yen, Chia-Jui; Chen, San-Chi; Lin, Yun-Tzu; LI-CHUN LU ; CHIH-HUNG HSU ; ANN-LII CHENG ; YU-YUN SHAO | Hepatology international | 14 | 14 | |
2012 | Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems | YU-YUN SHAO ; LI-CHUN LU ; ZHONG-ZHE LIN ; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | British Journal of Cancer | 26 | 26 | |
2014 | Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy | YU-YUN SHAO ; CHIH-HORNG WU ; LI-CHUN LU ; Chan S.-Y.; Ma Y.-Y.; Yen F.-C.; CHIH-HUNG HSU ; ANN-LII CHENG | Journal of Hepatology | 45 | 48 | |
2014 | Recent advances in the prevention of hepatocellular carcinoma recurrence | LI-CHUN LU ; ANN-LII CHENG ; Poon R.T.P. | Seminars in Liver Disease | 49 | 44 | |
2021 | Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites | GUO, JHE-CYUAN ; Lin, Chen Yuan; CHIA-CHI LIN ; TA-CHEN HUANG ; Lien, Ming Yu; LI-CHUN LU ; HUNG-YANG KUO ; CHIH-HUNG HSU | ONCOLOGY (United States) | 1 | 1 | |